Charles River Laboratories CRL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's cash & equivalents?
- Charles River Laboratories (CRL) reported cash & equivalents of $198.2M in Q1 2026.
- How has Charles River Laboratories's cash & equivalents changed year-over-year?
- Charles River Laboratories's cash & equivalents decreased by 14.5% year-over-year, from $231.73M to $198.2M.
- What is the long-term trend for Charles River Laboratories's cash & equivalents?
- Over 5 years (2020 to 2025), Charles River Laboratories's cash & equivalents has grown at a -1.5% compound annual growth rate (CAGR), from $233.12M to $216M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company currently holds.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and potential for investment, while a decrease may indicate heavy capital expenditure or debt repayment.
- How does cash & equivalents compare across companies?
- Peers in the contract research organization (CRO) space typically maintain sufficient cash to cover short-term operational fluctuations.